Percheron Therapeutics Limited (ASX:PER)

Australia · Delayed Price · Currency is AUD

0.0030

-0.0005 (-14.29%)

Jul 10, 2026, 3:32 PM AEST

-62.50% (1Y)

Market Cap	5.33M -51.0%
Revenue (ttm)	1.74M -9.5%
Net Income	-9.49M
EPS	-0.01
Shares Out	1.52B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,095,918
Open	0.0040
Previous Close	0.0035
Day's Range	0.0030 - 0.0040
52-Week Range	0.0030 - 0.0130
Beta	1.03
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 10, 2026

About Percheron Therapeutics

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company’s lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2000

Employees 8

Stock Exchange Australian Securities Exchange

Ticker Symbol PER

Full Company Profile

Financial Performance

In fiscal year 2025, Percheron Therapeutics's revenue was 1.80 million, a decrease of -39.32% compared to the previous year's 2.97 million. Losses were -14.92 million, 25.2% more than in 2024.

Financial Statements